{"id":24001,"date":"2020-09-18T00:00:00","date_gmt":"2020-09-18T04:00:00","guid":{"rendered":"https:\/\/www.cancerresearch.org\/media-room\/2020\/immunotherapy-drug-development-pipeline-growth\/"},"modified":"2022-09-12T14:11:46","modified_gmt":"2022-09-12T18:11:46","slug":"immunotherapy-drug-development-pipeline-growth","status":"publish","type":"cri_news","link":"https:\/\/www.cancerresearch.org\/es\/media-room\/immunotherapy-drug-development-pipeline-growth","title":{"rendered":"Los f\u00e1rmacos de inmunoterapia en fase de desarrollo siguen creciendo de manera significativa en 2020 pese al impacto mundial de la pandemia\ufffc"},"content":{"rendered":"\n

NUEVA YORK, 18 de septiembre de 2020 \u2014 Pese al impacto de la pandemia de la COVID-19 en todo el mundo, ha resurgido el inter\u00e9s en el desarrollo cl\u00ednico y precl\u00ednico de la inmunooncolog\u00eda, lo que da esperanzas a los pacientes con c\u00e1ncer y a sus m\u00e9dicos tratantes. El volumen de investigaciones cl\u00ednicas que prueban terapias de inmunooncolog\u00eda para el tratamiento del c\u00e1ncer sigue aumentando, con cientos de nuevas terapias celulares que se suman a la fase de investigaci\u00f3n cada a\u00f1o, junto con una expansi\u00f3n de inmunomoduladores dirigidos a otros componentes del sistema inmunitario m\u00e1s all\u00e1 de los linfocitos T, que hasta ahora lideraban las aprobaciones de inmunoterapia contra el c\u00e1ncer a nivel mundial.<\/p>\n\n\n\n

La \u00faltima actualizaci\u00f3n anual del CRI sobre la situaci\u00f3n de la inmunooncolog\u00eda<\/a>, publicada hoy en Nature Reviews Drug Discovery, muestra la diversidad y el r\u00e1pido y continuo aumento de los f\u00e1rmacos de inmunooncolog\u00eda en fase de desarrollo cl\u00ednico y precl\u00ednico. Seg\u00fan el informe, los f\u00e1rmacos de inmunooncolog\u00eda en fase de desarrollo aumentaron en un 22 % de 2019 a 2020, lo que representa un aumento interanual mayor al observado de 2018 a 2019. En general, este crecimiento equivale a un aumento del 233% desde el primer informe del CRI sobre la situaci\u00f3n de la inmunooncolog\u00eda, publicado hace apenas tres a\u00f1os.<\/p>\n\n\n\n

El \u00faltimo informe del CRI sobre la situaci\u00f3n de la inmunooncolog\u00eda tambi\u00e9n muestra que, como en a\u00f1os anteriores, sigue aumentando el desarrollo cl\u00ednico de nuevos inmunomoduladores de c\u00e9lulas T, moduladores de otras c\u00e9lulas inmunitarias y terapias celulares. En general, los principales blancos activos para los tratamientos de inmunooncolog\u00eda son la CD19, los ant\u00edgenos asociados a tumores (AAT) y la v\u00eda PD-L1. Sin embargo, la cantidad de agentes dirigidos a los AAT generales disminuy\u00f3 en 2020 comparado con 2019, lo que puede deberse a la p\u00e9rdida de prioridad de las vacunas contra el c\u00e1ncer. Este descenso se recuper\u00f3 en el \u00faltimo a\u00f1o, en parte debido a las nuevas vacunas precl\u00ednicas contra el c\u00e1ncer basadas en neoant\u00edgenos y que utilizan tecnolog\u00eda de nanopart\u00edculas.<\/p>\n\n\n\n

\u00abEl Cancer Research Institute considera que este continuo y firme inter\u00e9s en la investigaci\u00f3n de la inmunooncolog\u00eda, en particular en medio de la pandemia que ha afectado significativamente a la comunidad cient\u00edfica, demuestra que la expansi\u00f3n transformadora del desarrollo del tratamiento de inmunooncolog\u00eda est\u00e1 lejos de terminar\u00bb, dijo Samik Upadhaya, Ph. D., analista de investigaci\u00f3n del CRI y principal autor del informe.<\/p>\n\n\n\n

El an\u00e1lisis tambi\u00e9n revela que en 2020 aument\u00f3 un 14% el n\u00famero de ensayos cl\u00ednicos activos en los que se prueban agentes de inmunooncolog\u00eda, en comparaci\u00f3n con 2019. Coincidente con el inicio y el pico de la pandemia de la COVID-19, hubo una disminuci\u00f3n de ensayos nuevos en comparaci\u00f3n con los a\u00f1os anteriores. Sin embargo, en los \u00faltimos meses ha habido un repunte de nuevos ensayos, que los autores predicen deber\u00eda mantener una trayectoria ascendente en 2020.<\/p>\n\n\n\n

\u00abEste an\u00e1lisis afirma que los tratamientos de inmunooncolog\u00eda son un pilar para los tratamientos actuales contra el c\u00e1ncer, y probablemente mantengan la tendencia creciente en los pr\u00f3ximos a\u00f1os por el bien de los pacientes con c\u00e1ncer\u00bb, dijo Jill O\u2019Donnell-Tormey, Ph. D., Directora Ejecutiva y de Asuntos Cient\u00edficos del CRI.<\/p>\n\n\n\n

Los an\u00e1lisis, como el llevado a cabo por el CRI, pueden ayudar a las empresas farmac\u00e9uticas a planificar sus estrategias de investigaci\u00f3n y generar asociaciones productivas para el desarrollo y la comercializaci\u00f3n de estos preciados tratamientos contra el c\u00e1ncer.<\/p>\n\n\n\n

Referencia:<\/strong>
Upadhaya et al. Immuno-oncology drug development forges on despite COVID-19<\/a>. Nature Reviews Drug Discovery, septiembre de 2020<\/em><\/p>\n\n\n\n

Enlace relacionado: Vea el panel interactivo del CRI que refleja los datos m\u00e1s recientes de la situaci\u00f3n de la inmunooncolog\u00eda en cancerresearch.org\/IO-landscape<\/a><\/p>\n\n\n\n

Contacto con los medios:<\/strong>
Brian Brewer, +1.212.688.7515 x242,\u00a0bbrewer@cancerresearch.org<\/a><\/p>\n\n\n\n\n\n

Acerca del<\/strong> Cancer Research Institute<\/strong>
El Cancer Research Institute (CRI), fundado en 1953, es una organizaci\u00f3n estadounidense sin fines de lucro y muy bien valorada, consagrada exclusivamente a salvar vidas al promover el descubrimiento y desarrollo de inmunoterapias eficaces para todos los tipos de c\u00e1ncer. Asesorado por un Consejo Asesor Cient\u00edfico de renombre mundial, que incluye a cuatro premios Nobel y 26 miembros de la Academia Nacional de Ciencias, el CRI ha invertido 445 millones de d\u00f3lares para apoyar la investigaci\u00f3n que realizan los inmun\u00f3logos e inmun\u00f3logos tumorales de los centros m\u00e9dicos y universidades m\u00e1s destacados del mundo. Asimismo, el CRI ha contribuido a lograr muchos de los principales avances cient\u00edficos que demuestran el potencial de la inmunoterapia para cambiar la manera de tratar el c\u00e1ncer. Para obtener m\u00e1s informaci\u00f3n, visite el sitio cancerresearch.org<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.<\/p>\n","protected":false},"featured_media":14318,"template":"","tags":[401,426,427],"resource_cancer_types":[],"resource_patient_age":[],"resource_cancer_stage":[],"resource_treatment_type":[],"resource_treatment_status":[],"class_list":["post-24001","cri_news","type-cri_news","status-publish","has-post-thumbnail","hentry","tag-clinical-accelerator-es","tag-io-landscape-es","tag-publications-es"],"acf":[],"yoast_head":"\nIO Drug Development Pipeline Continues Significant Growth in 2020<\/title>\n<meta name=\"description\" content=\"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IO Drug Development Pipeline Continues Significant Growth in 2020\" \/>\n<meta property=\"og:description\" content=\"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2022-09-12T18:11:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/37679048-b1ea-4d84-87e4-28efdee07a32.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"IO Drug Development Pipeline Continues Significant Growth in 2020\" \/>\n<meta name=\"twitter:description\" content=\"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/37679048-b1ea-4d84-87e4-28efdee07a32.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth\",\"url\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth\",\"name\":\"IO Drug Development Pipeline Continues Significant Growth in 2020\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg\",\"datePublished\":\"2020-09-18T04:00:00+00:00\",\"dateModified\":\"2022-09-12T18:11:46+00:00\",\"description\":\"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg\",\"width\":700,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Media Room Article\",\"item\":\"https:\/\/www.cancerresearch.org\/media-room\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Los f\u00e1rmacos de inmunoterapia en fase de desarrollo siguen creciendo de manera significativa en 2020 pese al impacto mundial de la pandemia\ufffc\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IO Drug Development Pipeline Continues Significant Growth in 2020","description":"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth","og_locale":"es_ES","og_type":"article","og_title":"IO Drug Development Pipeline Continues Significant Growth in 2020","og_description":"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.","og_url":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth","og_site_name":"Cancer Research Institute","article_modified_time":"2022-09-12T18:11:46+00:00","og_image":[{"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/37679048-b1ea-4d84-87e4-28efdee07a32.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"IO Drug Development Pipeline Continues Significant Growth in 2020","twitter_description":"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.","twitter_image":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/37679048-b1ea-4d84-87e4-28efdee07a32.jpg","twitter_misc":{"Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth","url":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth","name":"IO Drug Development Pipeline Continues Significant Growth in 2020","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg","datePublished":"2020-09-18T04:00:00+00:00","dateModified":"2022-09-12T18:11:46+00:00","description":"Immunotherapy drug development pipeline continues significant growth in 2020 despite global pandemic impact.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2022\/06\/0661071a-6e3f-4bf8-b5e7-29e5923fa324.jpg","width":700,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/media-room\/immunotherapy-drug-development-pipeline-growth#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Media Room Article","item":"https:\/\/www.cancerresearch.org\/media-room"},{"@type":"ListItem","position":3,"name":"Los f\u00e1rmacos de inmunoterapia en fase de desarrollo siguen creciendo de manera significativa en 2020 pese al impacto mundial de la pandemia\ufffc"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news\/24001","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_news"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/14318"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=24001"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tags?post=24001"},{"taxonomy":"resource_cancer_types","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_types?post=24001"},{"taxonomy":"resource_patient_age","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_patient_age?post=24001"},{"taxonomy":"resource_cancer_stage","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_cancer_stage?post=24001"},{"taxonomy":"resource_treatment_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_type?post=24001"},{"taxonomy":"resource_treatment_status","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/resource_treatment_status?post=24001"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}